PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX

Trial Profile

PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Advaxis
  • Most Recent Events

    • 15 May 2017 According to an Advaxis media release, Sharad Ghamande from Georgia Cancer Center at Augusta University is the principal investigator of this trial.
    • 27 Mar 2017 According to an Advaxis media release, one patient from this trial was featured in the Augusta Chronicle.
    • 27 Mar 2017 Results from Phase I portion (n=9) published in an Advaxis Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top